Working… Menu

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04743661
Recruitment Status : Not yet recruiting
First Posted : February 8, 2021
Last Update Posted : February 8, 2021
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics, Inc
Information provided by (Responsible Party):
Pediatric Brain Tumor Consortium

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : July 30, 2027
Estimated Study Completion Date : July 30, 2030